Efficacy DataThe company's commentary around early results on safety and efficacy of Cohort 8 in the Phase 2a portion of the RESOLVE study was very positive and supports the potential for EP-104GI.
Market PotentialEupraxia has the potential for a best-in-class treatment for the ever-growing eosinophilic esophagitis (EoE) market, and has shown the potential for an annual treatment of EP-104GI in this condition, which could grow to a ~1M addressable patient market.
Safety ProfileEP-104GI demonstrated a favorable safety profile, with plasma fluticasone levels remaining low and consistent, and no serious adverse events reported.